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ABSTRACT
Notch receptors have large extracellular domains containing up to 36 tandem epidermal
growth factor-like (EGF) repeats, which facilitate cell signaling by binding ligands on
neighboring cells. Notch receptors play major roles in a variety of developmental processes by
controlling cell fate decisions. Each EGF repeat consists of about 40 amino acids with 3
conserved disulfide bonds. Many of the EGF repeats are modified by O-linked fucose glycans,
and more than half have calcium-binding sites, but the sequences of the EGF repeats vary giving
distinct roles to each repeat. EGF repeat 27 (EGF27) from mouse NOTCH1 is modified with Ofucose and is 1 of 7 repeats that is differentially modified by specific Fringe enzymes, which are
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known to regulate NOTCH1 activation and ligand binding. To better understand the role of
EGF27 in NOTCH1 function and regulation, the 3-dimensional structures of EGF27 and its
glycoforms are being pursued. E. coli cells were used to produce EGF27 in sufficient quantities
for nuclear magnetic resonance analysis. Previous attempts to express the repeat alone and
refold the repeat under a steady redox environment were unsuccessful due to low yields and
extensive mixed-disulfide bond cross-linking. A new strategy using a cleavable maltose binding
protein fusion tag increased the solubility and yield of EGF27. With the fusion tag, EGF27 was
refolded to produce the correct disulfide bond arrangement, which was verified enzymatically
with the glycosyltransferases, Protein O-fucosyltransferase 1 (POFUT1) and Lunatic Fringe.

KEYWORDS: Notch, EGF, glycosylation, Fringe, Abruptex, NMR
GRAPHICAL ABSTRACT

ABBREVIATIONS
ECD, extracellular domain; LBD, ligand binding domain; EGF, epidermal growth factor-like;
Fuc, fucose; GlcNAc, N-acetylglucosamine; Gal, galatose; NeuAc, N-acetylneuraminic acid;
Xyl, xylose; Glc, glucose; NMR, nuclear magnetic resonance; POFUT1, Protein Ofucosyltransferase 1; TEV, tobacco etch virus protease; MBP, maltose binding protein; His6, 6X2

histidine

tag;

IPTG,

isopropyl

β-D-1-thiogalactopyranoside;

Tris,

tris(hydroxymethyl)aminomethane hydrochloride; Ni-IMAC, nickel-charged immobilized metal
affinity chromatography; FPLC, fast protein liquid chromatography system; SDS-PAGE, sodium
dodecyl sulfate-polyacrylamide gel electrophoresis; TFA, trifluoroacetic acid; MALDI, matrixassisted laser desorption ionization; MS, mass spectrometry; LFNG, Lunatic Fringe; DTT,
dithiothreitol; HPLC, high performance liquid chromatography; EICs, extracted ion
chromatograms.
HIGHLIGHTS
•

Recombinant expression of mouse NOTCH1 EGF27 in E. coli using M9 medium

•

TEV cleavable MBP fusion avoids intermolecular disulfide cross-linking

•

Steady redox refolding increases the yield of the correct disulfide isomer

•

Refolded EGF27 is a substrate of Protein O-fucosyltransferase 1 and Lunatic Fringe

•

Suitable yields for biophysical and structural biology studies
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1. Introduction
Notch receptors are transmembrane proteins that play an integral role in the development
of metazoans [1].

Notch receptors are comprised of a large extracellular domain (ECD)

including a negative regulatory region, a transmembrane domain, and an intracellular domain.
The signaling of Notch is activated by receptor–ligand interactions between the ECD and ligands
of the Delta or Serrate/Jagged families on neighboring cells. Upon activation, proteolysis
releases the Notch intracellular domain, which translocates to the nucleus for the transcription of
Notch targets. Two regions in the ECD that have been implicated in ligand binding and Notch
function are the ligand binding domain (LBD) and the Abruptex region (Fig. 1) [2-6]. Recent
structural studies reveal direct contacts between residues in the LBD with ligand [6, 7]. The
Abruptex region is defined by a series of mutations in Drosophila Notch that result in
hyperactivation of Notch activity [5].

Fig. 1. Domain map of mouse NOTCH1 ECD. Epidermal growth factor-like (EGF) repeats are
represented by numbered ovals, and the ligand binding domain (LBD) and Abruptex regions are
indicated with gray boxes. EGF repeats modified with O-fucosylation at the consensus
sequence, C2X4(S/T)C3, where Cn is the nth conserved cysteine in the EGF repeat sequence, are
indicated by red triangles (Fuc, fucose) [8, 9]. Elongation of O-fucose at selective EGF repeats
with N-acetylglucosamine (GlcNAc, blue square), galactose (Gal, yellow circle), and Nacetylneuraminic acid (NeuAc, purple diamond) is based on data from Kakuda and Haltiwanger,
2017 [9]. Asterisks indicate O-fucosylated EGF repeats that show different glycan elongation as
a result of specific Fringe activity [9]. The green hexagons indicate EGF repeats with a calcium
binding consensus sequence of (D/N)X(D/N)(D/Q)C1XnC3X(D/N) [10]. An orange tilde (~)
indicates tandem repeats that contain interdomain hydrophobic packing residues with a
consensus sequence of (F/Y/W)X4C6’XnC3X(D/N)X(I/L/V/P), where Cn’ and Cn are the
conserved cysteine residues in the N-terminal and C-terminal repeat sequences, respectively [11].
4

Notch receptor ECDs contain up to 36 tandem epidermal growth factor-like (EGF)
repeats. EGF repeats are relatively small domains that contain about 40 amino acids with six
cysteines forming three disulfide bonds in a conserved arrangement: C1–C3, C2–C4, and C5–C6,
where Cn is the nth conserved cysteine in the repeat sequence. The degree of rigidity between
tandem EGF repeats is variable and attributed to calcium binding and inter-repeat hydrophobic
packing. Calcium binding sites are in conserved positions along the ECD and occur in the linker
region between many of the tandem EGF repeats (Fig. 1, green hexagons) [10, 12]. Structural
studies have shown that calcium binding rigidifies the linker between repeats, and inter-repeat
hydrophobic packing (Fig. 1, orange tildes) can further stabilize the linker region [11, 13, 14].
The combination of a calcium binding site and inter-repeat hydrophobic packing was shown to
increase the affinity for calcium [13, 15]. In the absence of a calcium binding consensus
sequence, the linker region is flexible [16]. The highest concentration of predicted flexibility in
mouse NOTCH1 occurs at both ends of the ECD and in the Abruptex region (Fig. 1). Several
Notch EGF repeats also contain conserved consensus sequences for three types of O-linked
glycans: O-fucose, O-glucose, and O-N-acetylglucosamine [17-19]. The O-glucose form is
typically the trisaccaharide, Xyl-α1,3-Xyl-α1,3-Glc (Xyl, xylose; Glc, glucose), and the O-fucose
form (Fig. 1, red triangles) can be elongated to di-, tri-, and tetrasaccharide (NeuAc-α2,3/6-Galβ1,4-GlcNAc-β1,3-Fuc) forms.

Glycosylation of the EGF repeats directly affects the regulation of the Notch signaling
pathway [20-22]. Many of the EGF repeats (17 of 36) in mouse NOTCH1 are modified by Ofucose, and a subset of these are elongated with a β1,3-linked GlcNAc by one or more of the
Fringe enzymes, Lunatic, Manic, or Radical Fringe [9]. Modification by each Fringe results in
specific elongation profiles of the NOTCH1 ECD with differences at 7 EGF repeats (Fig. 1,
5

asterisks). The Fringe enzymes are known modulators of Notch signaling [9, 23]. Mutations of
the O-fucose sites in the LBD and the Abruptex region directly affect NOTCH1 activity and
reduce the ability of Fringes to modulate its activity [9, 24]. While the mutations in the Abruptex
region had variable effects depending on the cells used for the Notch activity assays, loss of the
O-fucose modification on EGF12 (part of the LBD) had significant effects on Notch function in
cell-based assays and in vivo [9, 23-25]. The recent co-crystal structures of NOTCH1 LBD and
portions of DELTA-LIKE 4 or JAGGED1 show that the O-fucose on EGF12 is in direct contact
with ligand, providing a structural explanation for the importance of this O-fucose in Notch
function [6, 7].
Less is known about the Abruptex region since no structures are currently available for
any of the EGF repeats in this part of the Notch ECD. Our group is interested in studying the 3dimensional structure of this region to understand the role of glycosylation on Notch function.
Our first target is mouse NOTCH1 EGF27, which is modified by O-fucose and elongated with a
β1,3-GlcNAc by Fringes in cells [9, 24]. Lunatic Fringe (LNFG) and Manic Fringe modify the

O-fucose resulting in a mixture of trisaccharide and tetrasaccharide glycans on EGF27 (Fig. 1)
[9]. Radical Fringe does not modify O-fucose on EGF27, and elimination of the O-fucose site
alters NOTCH1 activity in cell based assays [9, 24]. Nuclear magnetic resonance (NMR)
spectroscopy is a great tool for studying glycosylated proteins, which tend to be dynamic and not
crystallize well. For NMR studies, proteins are typically produced with

15N-

and

13C-isotopes

through metabolic labeling using E. coli. For EGF repeats, E. coli expression does not always
produce the protein with the correct disulfide bond arrangement and can result in a mixture of
disulfide isoforms and highly cross-linked protein (via intermolecular disulfide bonds). Bacterial
expression of EGF27 results in two major disulfide isoforms, but the correct form is selectively
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glycosylated by Protein O-fucosyltransferase 1 (POFUT1) and UDP-glucose:protein Oglucosyltransferase 1, POGLUT1/Rumi [26, 27], giving a means of identifying the native
isoform. In addition, the small size of the EGF repeats (5-7 kDa) can make purification and
sample concentrating difficult. The yield of protein has to be high (hundreds of micrograms to
milligrams per liter culture) due to the cost of labeled media.

Our group has previously

attempted to produce properly folded EGF27 using a variety of strategies, including varying the
N-terminal sequence, using enhanced green fluorescence protein as a cleavable fusion tag,
resolubilization and refolding methods, and varying the E. coli expression strain and growth
conditions [28, 29]. In this article, we present a new method for producing EGF27 in high yield
with the native disulfide bond arrangement by using a tobacco etch virus protease (TEV)
cleavable maltose binding protein (MBP) fusion and redox refolding.
2. Materials and methods
2.1. Materials
The recombinant expression plasmid, pMHTΔ238, was purchased from the DNASU
Plasmid Repository (clone #TvCD00084286) [30] and encodes the self-cleaving N-terminal
fusion protein of MBP, a 7X-histidine tag, and a mutated and truncated form of TEV protease
[31]. TEV protease was expressed from the pMHTΔ238 plasmid in Rosetta 2(DE3) E. coli cells
as described in Blommel and Fox with a few modifications [31] (detail in the Supplementary
Data). pET-28a(+) vector (catalog #69864-3) and Rosetta 2(DE3) E. coli cells (catalog #713973) were purchased from Novagen (EMD Millipore). pMAL-c5X vector (catalog #N8108S) was
purchased from New England Biolabs. All water used was supplied from a Millipore Direct-Q 3
ultrapure water system.
7

2.2. EGF27 expression vectors
The pMAL-TEV-EGF27 expression plasmid was produced through a series of cloning
experiments starting with pET20b-EGF27 described in Takeuchi et al. [26]. The expression
plasmid, pET28-EGF27, was produced by subcloning EGF27 from pET20b-EGF27 using NcoI
and XhoI restriction sites [29]. pET28-EGF27 encodes the EGF27 domain (mouse NOTCH1
(UniProtKB Q01705) amino acids 1021-1062) with a C-terminal 6X-histidine tag (His6). The
pMAL-TEV-EGF27 plasmid was produced by amplifying EGF27 and the C-terminal His6
sequences from pET28-EGF27 using the primers: 5’-CGTCCATATGGAAAACCTGTACTTCCAGTCGGATGTCAATGAGTGT and

3’-CGCAGTCGACGTTAGCAGCCGGATCTCA.

The forward primer included an NdeI restriction site followed by the sequence that encodes the
tobacco etch virus recognition sequence, and the reverse primer included a SalI restriction site.
The amplicon and pMAL-c5x were cut with NdeI and SalI restriction enzymes followed by
ligation. The resulting pMAL-TEV-EGF27 plasmid encodes the fusion protein referred to as
MBP-EGF27 and includes the cytosolic maltose binding protein followed by a TEV protease
cleavage site, the EGF27 domain (amino acids 1021-1062), and a C-terminal His6. All plasmid
sequences were confirmed by sequencing in the Louisiana State University GeneLab.
2.3. MBP-EGF27 protein expression and purification
MBP-EGF27 was expressed in Rosetta 2(DE3) E. coli cells in minimal M9 medium with
ampicillin (50 μg/mL) and chloramphenicol (35 μg/mL) for antibiotic selection. Minimal M9
medium is necessary to produce metabolically labeled protein for NMR studies. Even though
magnetic isotopes were not incorporated here, testing the yield from minimal M9 medium is
8

necessary due to the significant differences often observed between expression in LB versus M9
media. The strategy described by Marley et al. [32], where the expression cells are grown in rich
medium and then exchanged into minimal medium before induction, was implemented. LB
medium (1 L) was inoculated with 50 mL of starter culture grown from a single colony at 37 °C
with 250 rpm shaking for 16 h. The 1 L cultures were incubated at 37 °C with 250 rpm shaking
until an optical density of 0.5 - 0.6 at 600 nm was reached. The LB medium was exchanged to
minimal M9 medium [M9 salts (50 mM Na2HPO4, 20 mM KH2PO4, 10 mM NaCl, 18 mM (1.0
g/L) NH4Cl), 2 mM MgSO4, 0.1 mM CaCl2, 1X BME vitamins, 3.0 mM (1.0 mg/L) thiamine
hydrochloride, 1X trace metal solution [33], and 22 mM (4.0 g/L) glucose], and the culture was
incubated at 37 °C with 250 rpm shaking for 1 h. The expression of MBP-EGF27 was induced
by adding 0.3 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) to the minimal medium. The
cultures were incubated at 16 °C with 250 rpm shaking for 16 h. The cells were harvested by
centrifugation at 3,000 x g for 10 min at 4 °C and suspended in 20 mL of Tris buffer (125 mM
tris(hydroxymethyl)aminomethane hydrochloride (Tris) and 175 mM NaCl at pH 7.0). The cells
were either stored at -80 °C or processed for protein purification.
Suspension of bacterial cell pellets (20 mL) from the expressions were prepared for lysis
by adding 1.5 mL of CelLytic B cell lysis reagent, ½ SigmaFAST EDTA-free protease inhibitor
tablet, 1 μL (250 units) of endonuclease, and approximately 5 mg of phenylmethane sulfonyl
fluoride. The cells were lysed using a French pressure cell followed by centrifugation at 25,000
x g for 30 min at 4 °C to obtain soluble protein in the cleared lysate. The cleared lysate was
loaded onto 5 mL of nickel-charged immobilized metal affinity chromatography (Ni-IMAC)
resin in a 1 cm inner diameter column at a flow rate of 1 mL/min using a fast protein liquid
chromatography (FPLC) system. The captured proteins were washed with 30 mL of Tris wash
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buffer (50 mM Tris, 300 mM NaCl, 5% glycerol, and 5 mM imidazole at pH 7.0), and eluted
with 20 mL Tris elution buffer (50 mM Tris, 300 mM NaCl, 5% glycerol, and 250 mM
imidazole at pH 7.0). The eluted proteins were detected using absorbance at 280 nm and pooled
from 2 mL fractions (typically 8 - 10 mL). The Bradford protein assay was used to analyze the
protein concentration following the 96-well plate instructions (Pierce Comassie Plus Assay Kit,
ThermoFisher Scientific).

The Tris elution buffer was exchanged to 10 mM ammonium

bicarbonate buffer (1 L reservoir) using dialysis tubing at 12 °C for 16 h with stirring.
Samples of the expression cultures, purification steps, and purified proteins were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Sample
aliquots (15 μL) were mixed with 15 µL of 2X Laemmli buffer with 5% (by volume) of βmercaptoethanol, heated at 85 °C for 5 min, and loaded into 4-20% Tris/glycine gels. The gels
were run at 100 V for 60 min in running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH
8.3 buffer) followed by staining with brilliant blue R-250 solution (1.0 g/L brilliant blue R-250
dye, 50% methanol, 40% water, and 10% acetic acid) for 1 h. After de-staining in 50% water,
40% methanol, 10% acetic acid, the gels were imaged using a Bio-Rad Gel Doc EZ System.
2.4. Refolding by disulfide isomerization and cleavage of the MBP-EGF27 protein
Non-native disufide bonds in EGF27 within the MBP-EGF27 fusion protein were
dissociated with reducing agent and reformed under a steady redox environment [34]. The
disulfide bonds were reduced by adding 15 mM dithiothreitol (DTT) to 3.0 mg/mL of MBPEGF27 in 10 mM ammonium bicarbonate buffer and incubating at 12 °C for 30 min. The DTTtreated MBP-EGF27 protein (8 – 10 mL) was placed in dialysis tubing and suspended in 100 mL
of redox refolding buffer (5 mM reduced glutathione, 0.5 mM oxidized glutathione, 10 mM
ammonium bicarbonate, and 0.5 M L-arginine at pH 5.8) overnight at 12 °C with stirring.
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The cleavage of the MBP-EGF27 protein with TEV protease was performed at an
enzyme: substrate ratio of 1:100 (mass:mass). An appropriate volume of TEV protease stock
solution (Supplemental Data) was added to the refolded MBP-EGF27, and the mixture was
incubated overnight at 4 °C. An aliquot of the mixture was analyzed by SDS-PAGE analysis, as
described earlier, to assess cleavage.
2.5. Purification, analysis, and validation of EGF27 isomers
EGF27 was purified from the mixture containing MBP and TEV protease by reverse
phase high performance liquid chromatography (HPLC). The mixture was prepared for HPLC
by adding 0.1% TFA and 5% acetonitrile. Aliquots of the mixture (2 mL) were injected into a
semi-prep C18 column (300 Å, 5 µm, 10 x 250 mm) and eluted with linear gradients of solvent
A (0.1% trifluoroacetic acid (TFA) in water) and solvent B (0.1% TFA in acetonitrile). The
elution profile was 0% to 45% solvent B at a flow rate of 1 mL/min followed by 45% to 90%
solvent B at a flow rate of 2 mL/min for 60 min. The eluent was monitored with a diode-array
detector at 210 nm and 280 nm and collected as 100 μL aliquots in 96-well plates. Peaks eluting
between 35 – 55 min were collected and lyophilized. Peak areas were calculated with the
PeakFit software using the second derivative method with Gaussian peak shapes, variable
amplitudes and widths, cubic baseline correction, and 1% smoothing.
Matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) was used
to determine the molecular weight of the species in each collected HPLC sample. On a MALDI
target plate, 1 µL of the sample was mixed with 1 µL of saturated sinapinic acid in 50%
acetonitrile/0.1% TFA in water.

The mixture was co-crystallized by evaporation at room

temperature. Data acquisition was performed on a Bruker UltrafleXtreme MALDI TOF/TOF in
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the reflectron positive ion mode with 1000 shots signal-averaged and a molecular weight range
of 4000 – 7000 Da.
2.6. Validation of EGF27 isomer structure by in vitro glycosylation
Production and purification of POFUT1-myc-His6 and Lunatic Fringe (LFNG)-Myc-His6
enzyme were performed as previously described in Luo et al. and Luther et al. [35, 36]. The in
vitro production of glycosylated EGF27 for MS analysis was performed as previously described
in Takeuchi et al. [26]. Briefly, in a total volume of 30 µL, 10.5 µg of EGF27 acceptor substrate
was mixed with 750 ng of POFUT1 and 1.5 µg of LFNG with 200 µM each of UDP-GlcNAc
and GDP-fucose donors. The reaction was buffered with 50 mM HEPES at pH 6.8 with 10 mM
MnCl2. The reaction was incubated for 6 h in a water bath at 37 °C at which point a further 750
ng of POFUT1 and 1.5 µg of LFNG were added and incubated for 6 h. A final addition of 1.5
µg of POFUT1 and 3 µg of LFNG was added, followed by incubation at 37 °C overnight. The

assay was stored at -20 °C awaiting MS analysis. The in vitro radioactive glycosylation of
EGF27

with

either

GDP-[2-3H]-fucose

or

UDP-[2-3H(N)]GlcNAc

donor

(American

Radiolabeled Chemicals) was performed as described previously in Luther et al. and Rampal et
al. [36, 37]. The fucosylation reaction contained 5 µg of EGF27, 1.5 µg of POFUT1 and 100
nCi of GDP-[2-3H]-fucose. The GlcNAcylation reaction contained 5 µg of EGF27, 1.5 µg of
POFUT1, 3 µg of LFNG, 200 µM GDP-fucose, and 45 nCi of UDP-[2-3H(N)]GlcNAc. The
reactions were incubated overnight at 37 °C, diluted with 900 µL of 50 mM EDTA, and stored at
-20 °C until purification and analysis.

The products were purified over a C18 cartridge

(Agilent), washed with 9 mL of H2O, eluted in 1 mL of 80% ethanol, mixed with 4 mL of
ScintiSafe Plus 50% liquid scintillation cocktail (Fisher Scientific), vortexed, and left in the dark
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overnight. The samples were scintillation counted for 2 minutes on a Perkin Elmer TriCarb 2910
TR Liquid Scintillation Analyzer.
MS data acquisition for EGF27 was performed as previously described in Takeuchi et al.
[38].

Production of extracted ion chromatograms (EIC) was performed using Xcalibur

QualBrowser (ThermoFisher Scientific). All observed peaks from the isotopic distribution of the
+7 m/z peak are included in the EIC and the peak values include ±10 ppm error.

3. Results and discussion
3.1. Expression, purification, and cleavage of the MBP-EGF27 fusion protein
The MBP-EGF27 fusion protein was expressed from pMAL-c5x-TEV-EGF27 in Rosetta
2(DE3) E. coli cells and purified using Ni-IMAC. Fig. 2 shows the SDS-PAGE analysis of the
expression, purification, and TEV protease cleavage of MBP-EGF27. Samples from the culture
before and after induction with IPTG (Fig. 2, lanes 1 and 2) show the appearance of a dark band
at 50 kDa, which corresponds to the overexpressed MBP-EGF27 fusion protein. The protein is
highly soluble as shown by the lysate sample (Fig. 2, lane 3). Ni-IMAC purification yielded
highly pure protein with a typical yield of 20 mg per L culture. The elution of MBP-EGF27 is
shown in Fig. 2, lane 5 (band i). Samples of MBP-EGF27 before and after TEV protease
digestion are shown in Fig. 2, lanes 6 and 7, respectively. These samples show nearly complete
digestion of the MBP-EGF27 protein with TEV protease (band iii) to produce MBP (band ii) and
cleaved EGF27 (band iv).
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Fig. 2. SDS-PAGE analysis of the expression, purification, and TEV protease digestion of
MBP-EGF27. Lane numbers are labeled along the bottom. Lanes 1 and 2 are the whole cell
lysate before and after induction with IPTG showing a dark band near 50 kDa in lane 2
corresponding to MBP-EGF27. Purification of MBP-EGF27 using Ni-IMAC is shown with
samples of the cleared lysate (lane 3), the lysate flow-through from the Ni-IMAC resin (lane 4),
and the elution from the Ni-IMAC resin with imidazole buffer (lane 5). In lane 5, the MBPEGF27 band is labeled (i). Lanes 6 and 7 are the purified MBP-EGF27 protein before and after
digestion with TEV protease. Lane 8 is Bio-Rad Precision Plus protein standard with the
molecular weights listed to the right in kDa. The migration position of MBP-EGF27 (49.8 kDa),
MBP (43.8 kDa), TEV (28.1 kDa), and EGF27 (6.0 kDa) are indicated with roman numerals, i –
iv, respectively. The gel images originated from the same gel; the image was split to remove
irrelevant lanes for clarity. The full gel image is included as Fig. S1.
3.2. Separation and analysis of cleaved EGF27
EGF27 can form different conformational isomers based on the presence and
arrangement of the three disulfide bonds. The native disulfide bond arrangement of EGF repeats
is C1–C3, C2–C4, and C5–C6. For the EGF27 domain, the disulfide bonds should be C1025C1036, C1030-C1045, and C1047-C1056.

When an EGF repeat is expressed in E. coli,

numerous isomers are possible especially considering different numbers and arrangements of
intramolecular disulfide bonds and oligomers formed through intermolecular disulfide bonds.
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The EGF27 isomers (and MBP) were separated using reverse-phase HPLC, and the proteins
were identified using MALDI MS and SDS-PAGE analyses.

Fig. 3. HPLC separation and analysis of cleaved EGF27. Mixtures of EGF27 and MBP were
separated using reverse-phase HPLC. (A) The chromatogram of the untreated sample shows 5
major peaks. The peaks labeled i, ii, and iii were confirmed to contain EGF27 based on MALDI
MS analysis. The peak labeled with an asterisk is unknown because it had a lower m/z than was
expected for EGF27. The large peak at 50.5 min was confirmed to be MBP by SDS-PAGE
analysis (Fig. S1, lane 8). (B) When the MBP-EGF27 fusion protein is reduced and refolded, the
cleaved EGF27 and MBP mixture shows the same 5 peaks as the untreated sample but with
different relative intensities for peaks i-iii. The refolded sample is enriched in the EGF27 isomer
corresponding to peak i.
Fig. 3A shows the HPLC chromatogram of the EGF27 and MBP mixture before redox
refolding. The presence of EGF27 was confirmed in the peaks labeled i, ii, and iii by MALDI
MS analysis (Fig. 4).

The resolution of the MALDI mass spectra is not high enough to

confidently identify the number of disulfide bonds in each isomer, but the m/z values at the peak
maxima fall within the range of EGF27 with 2 or 3 disulfide bonds (m/z 6048.6 or 6046.6,
respectively). Peaks ii and iii have additional higher molecular weight components at m/z of
6598.0 (+551.3) and 6353.6 (+306.2).

It is not clear whether these proteins are adducts,
15

modified proteins, or protease fragments. One possibility for the peak at m/z 6353.6 is the
addition of glutathione (+305) by the activity of an E. coli glutathione S-transferase. The peak
with a m/z 6598.0 may be a product of endogenous protease digestion within the TEV
recognition sequence leaving extra amino acids at the N-terminus (LYFQ-) with a calculated m/z
of 6598.8. The HPLC peak at 37.5 min (labeled with an asterisk in Fig. 3A) gave a MALDI MS
signal at a m/z of 4910.8 (Fig. S2); the peak is likely a truncated form of EGF27 because the m/z
corresponds with EGF27 minus the C-terminal tag (-ALEHHHHHH) with a calculated m/z of
4911.0. The HPLC peak at 50.5 min did not give a MALDI MS signal within the range of 4000
– 7000 Da, but SDS-PAGE analysis indicated that the peak is MBP (Fig. S1, lane 8).

Fig. 4. MALDI-MS analysis of HPLC peaks. MALDI mass spectra of samples from the
HPLC separation of the untreated sample are shown for (A) peak i, (B) peak ii, and (C) peak iii.
The calculated m/z for EGF27 with 3 disulfide bonds is 6046.6. Peak i contains EGF27, and
peaks ii and iii contain EGF27 and species at higher m/z.
To identify which EGF27 isomers contain disulfide bonds, the EGF27 and MBP mixture
was treated with DTT and analyzed with HPLC (Fig. S3). All EGF27 isomers (i, ii, and iii)
shifted in retention time after treatment with DTT, confirming at least one disulfide bond in each.
The fact that the peaks do not collapse into a single peak, but shift to several peaks with
16

shoulders, indicates that even with the disulfide bonds dissociated, there is a mixture of species,
which is consistent with the MALDI-MS analysis.
Since at least three isomers of EGF27 were produced in E. coli and the yield of EGF27
may be limited by the presence of oligomers of EGF27 (due to intermolecular disulfide bonds),
the MBP-EGF27 fusion protein was reduced and refolded under steady redox conditions. Initial
optimization of the redox buffer was performed using EGF27 expressed from pET20b-EGF27
(with no MBP fusion) [28]. The success of forming intramolecular disulfide bonds versus
intermolecular disulfide bonds depended on the concentration of EGF27 such that very low
concentrations (10 µg/mL) were needed [28].

The refolded EGF27 protein needed to be

concentrated 300-fold for NMR analysis, which resulted in significant loss of protein. To
overcome this limitation, EGF27 was reduced and refolded as part of the fusion protein, MBPEGF27. Even at a concentration of 3.0 mg/mL, the refolded MBP-EGF27 remained soluble.
The relatively large MBP likely prevents intermolecular disulfide bond formation by maintaining
EGF27-solubility during refolding and sterically hindering the intermolecular interactions of
EGF27 molecules.
To evaluate whether different isomers result from refolding, the fusion protein was
cleaved with TEV protease and purified by HPLC. Fig. 3B shows the HPLC chromatogram of
the refolded sample. Compared to Fig. 3A, peak i is enriched by 8-fold upon refolding while
peak ii decreases and peak iii remains unchanged (Table S1), indicating that the isomer in peak i
is the most stable one under the redox conditions used. The MBP is the same intensity in both
samples (Table S1 and Fig. S4), which is expected since it does not contain cysteine residues.
3.3. Confirmation of EGF27 disulfide bonds through glycosylation studies
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Li et al. have shown through co-crystallization of POFUT1 and EGFs that only a serine
or a preferred threonine in an appropriate consensus sequence between cysteines 2 and 3 of a
properly folded EGF can be modified by this enzyme [39].

LFNG can then modify the

fucosylated EGF with a GlcNAc [37]. Thus, we used modification by these enzymes as a
stringent test to confirm that the major EGF27 isomer (Fig. 3B, peak i) has the native disulfide
bond arrangement [27, 37, 39]. EGF27 is a native substrate of POFUT1 and LFNG and is
modified at T1035 with O-fucose by POFUT1 followed by the elongation of the glycan with a
β1,3-GlcNAc by LFNG [9].

Single point assays were performed with 3H-labeled donor

substrates (GDP-3H-fucose or UDP-3H-GlcNAc) to evaluate the EGF27 isomer as a substrate for
the glycosyltransferases. Fig. S5 shows robust incorporation of 3H-fucose into EGF27 when
incubated with POFUT1 and GDP-3H-fucose, and incorporation of 3H-GlcNAc when incubated
with POFUT1, GDP-fucose, LFNG, and UDP-3H-GlcNAc, indicating that the major EGF27
isomer has the correct disulfide bond arrangement.
To confirm the purity of the EGF27 isomer and extent of glycosylation, the same
reactions were performed without radioactivity and assessed by mass spectrometry. Shown in
Fig. 5 are the extracted ion chromatograms (EICs) for EGF27 untreated (Fig. 5A), EGF27
incubated with POFUT1 and GDP-fucose (Fig. 5B), and EGF27 incubated with POFUT1, GDPfucose, LFNG, and UDP-GlcNAc (Fig. 5C). It was observed that the protein was able to be fully
glycosylated in both its mono- and di-saccharide forms, further confirming that the EGF27
isoform from HPLC peak-i is in fact in its correct form with all the disulfide bonds intact.
Moreover, the absence of unmodified EGF27 in the mono- and di-saccharide samples indicates
that the EGF27 isomer is pure without traces of other co-eluting isomers.
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Fig. 5. Extracted ion chromatograms for the +7 charge state of (A) the unmodified form, (B) the
O-fucose monosaccharide form, and (C) the GlcNAc-Fucose disaccharide form of EGF27.
Each chromatogram includes three EICs at m/z of 865 (unmodified EGF27, black line), 886
(Fucα1-O-EGF27, gray line), and 915 (GlcNAcβ1-3Fucα1-O-EGF27, dashed black line).
4. Conclusions
In this study, a novel method to produce recombinant mouse NOTCH1 EGF27 with its
native disulfide bond arrangement was established. Developing this method was necessary to
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pursue 3-dimensional NMR structural studies of EGF27. For these studies, the yield of properly
folded EGF27 from E. coli expression must be on the order of hundreds of micrograms per liter
expression culture using minimal M9 medium. Various constructs of EGF27, including varying
the N-terminal sequence, expressing multiple EGF repeats in tandem, and using an enhanced
green fluorescent protein fusion, were tested for expression in multiple E. coli cell lines over
many years [28, 29]. The yields were either low or recovering the small EGF27 protein proved
difficult. One challenge that was overcome by using the MBP fusion was the loss of EGF27
during concentration of the protein following the redox refolding step. The MBP fusion allows
for high concentrations (3.0 mg/mL) of MBP-EGF27 to be reduced and refolded without the
formation of intermolecular disulfide bonds. The MBP-EGF27 protein produced in E. coli
consists of at least three isoforms of EGF27 as determined by varying retention times in reverse
phase HPLC and MALDI-MS analysis. The native disulfide arrangement of the EGF27 isoform
eluting in peak-i was validated by glycosylation assays using POFUT1 and LFNG. Redox
refolding increased the yield of the properly folded EGF27 by 8-fold. We anticipate that this
expression and purification method will be applicable to other single and tandem EGF repeat
domains as we continue to pursue structural characterization of the NOTCH1 Abruptex region.
With the increased yield of EGF27, structural studies of EGF27 with and without its native
glycosylation are being pursued.
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